دورية أكاديمية
Drug hypersensitivity in drug-resistant tuberculosis.
| العنوان: | Drug hypersensitivity in drug-resistant tuberculosis. |
|---|---|
| المؤلفون: | Katran ZY; Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey., Bulut İ; Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey., Babalık A; Department of Chest Diseases, University of Health Sciences, Süreyyapaşa Training and Research Hospital, İstanbul, Turkey., Keren M; Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey., Tepetam FM; Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey., Mersin SS; Department of Allergy and Immunology, Dr Ersin Arslan Training and Research Hospital, Gazıantep, Turkey., Örçen C; Department of Allergy and Immunology, Derınce Training and Research Hospital, Kocaeli, Turkey., Yakut T; Department of Allergy and Immunology, Diyarbakır Training and Research Hospital, Diyarbakır, Turkey., Yavuz D; Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey. |
| المصدر: | The World Allergy Organization journal [World Allergy Organ J] 2023 May 20; Vol. 16 (5), pp. 100778. Date of Electronic Publication: 2023 May 20 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101481283 Publication Model: eCollection Cited Medium: Print ISSN: 1939-4551 (Print) Linking ISSN: 19394551 NLM ISO Abbreviation: World Allergy Organ J Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2019- : [Atlanta, GA] : Elsevier Inc. Original Publication: [Philadelphia, PA] : Lippincott Williams & Wilkins |
| مستخلص: | Objective: To evaluate drug resıstant tuberculosis patients who developed drug hypersensitivity to antituberculosis drug. Methods: This was a retrospective study. The primary aim of the study is to determine the demographic and clinical characteristics of patients who develop drug hypersensitivity in drug resistant tuberculosis patients. The secondary aim of the study is to examine the treatment results. Demographic features, tuberculosis diagnostic indicator, clinical signs of developing hypersensitivity reaction, reaction time, and treatment were evaluated. Results: A total of 25 patients were included in the study. The prevalence of hypersensitivity in drug resistance patients was 11.9%. Twelve (48%) of the cases were women. Mean age (mean ± SD) was 37.24 ± 14.44 years; early type hypersensitivity reaction in 13 (52%). Three patients were isoniazid resistant; 19 patients were multidrug-resistant (MDR); 2 patients were pre-extensive drug resistant (Pre-XDR), 1 patient was extensive drug resistance (XDR) tuberculosis. The most common skin findings were maculopapular eruption and urticaria. But also we had seen ısole angıodema, urtıcarıa and angıoedema, erythema multıforme, lıchenoıd drug eruptıon and drug rash with eosinophilia and systemic symptoms. In patients who developed a hypersensitivity reaction, the responsible agent was identified in 14 cases in total. Among the drugs, pyrazinamide, ethambutol, moxifloxacin, amikacin, para amino salicylic, prothionamide, and cycloserine are the responsible agents. When evaluated in terms of treatment results, 15 (60%) patients successfully completed the treatment. Conclusion: Our study is the first study in the literature that evaluated the drug hypersensitivity in drug resıstance tuberculosis patients. Drug hypersensitivity that develops with tuberculosis treatment may lead to discontinuation or change in treatment. İt can cause treatment failure, drug resistance, relapse, and even death. In resistant tuberculosis, the already existing resistance pattern may become more difficult to treat. Success can be achieved with the right management in these patients who have few treatment options, more drug side effects, and high treatment failure rates. The established regimen should be curative and prevent recurrence. (© 2023 The Authors.) |
| References: | Front Med (Lausanne). 2022 Mar 01;8:790718. (PMID: 35300176) Lancet Respir Med. 2020 Apr;8(4):383-394. (PMID: 32192585) Med J Malaysia. 2007 Jun;62(2):143-6. (PMID: 18705448) Lancet Infect Dis. 2017 Sep;17(9):898. (PMID: 28845791) Patient Prefer Adherence. 2021 Nov 23;15:2597-2607. (PMID: 34848950) Front Pharmacol. 2022 Jun 02;13:883483. (PMID: 35747749) J Clin Tuberc Other Mycobact Dis. 2021 Jan 27;23:100221. (PMID: 33553682) Monaldi Arch Chest Dis. 2020 Mar 30;90(1):. (PMID: 32231347) PLoS One. 2021 Oct 29;16(10):e0259221. (PMID: 34714879) Infect Drug Resist. 2022 Apr 21;15:2055-2065. (PMID: 35480059) Pulmonology. 2021 Jan-Feb;27(1):77-79. (PMID: 32444311) Int J Tuberc Lung Dis. 1997 Apr;1(2):187-90. (PMID: 9441086) Front Pharmacol. 2022 May 17;13:876955. (PMID: 35656303) South Med Rev. 2012 Jul;5(1):6-13. (PMID: 23093894) Lancet. 2018 Sep 8;392(10150):821-834. (PMID: 30215381) Int J Infect Dis. 2021 Jun;107:86-91. (PMID: 33823278) Indian Dermatol Online J. 2020 Mar 09;11(2):177-181. (PMID: 32477975) Thorax. 2006 Sep;61(9):791-4. (PMID: 16844730) Indian J Dermatol. 2022 Jan-Feb;67(1):77-79. (PMID: 35656242) Allergy Asthma Clin Immunol. 2022 Nov 21;18(1):97. (PMID: 36414980) Inflamm Allergy Drug Targets. 2014;13(4):241-8. (PMID: 25039910) Thorax. 1998 Jul;53(7):536-48. (PMID: 9797751) Allergy. 2014 Apr;69(4):420-37. (PMID: 24697291) |
| فهرسة مساهمة: | Keywords: Drug resıstance tuberculosis; Maculopapular drug eruptıon; Pyrazınamıde; Urticaria |
| تواريخ الأحداث: | Date Created: 20230530 Latest Revision: 20230531 |
| رمز التحديث: | 20230531 |
| مُعرف محوري في PubMed: | PMC10213312 |
| DOI: | 10.1016/j.waojou.2023.100778 |
| PMID: | 37251814 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1939-4551 |
|---|---|
| DOI: | 10.1016/j.waojou.2023.100778 |